Cargando…

Target Therapy in Hematological Malignances: New Monoclonal Antibodies

Apart from radio- and chemotherapy, monoclonal antibodies (MoAbs) represent a new, more selective tool in the treatment of hematological malignancies. MoAbs bind with the specific antigens of the tumors. This interaction is a basis for targeted therapies which exhibit few side effects and significan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Podhorecka, Monika, Markowicz, Justyna, Szymczyk, Agnieszka, Pawlowski, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897146/ https://www.ncbi.nlm.nih.gov/pubmed/27433507 http://dx.doi.org/10.1155/2014/701493

Ejemplares similares

Abnormal microRNA expression in the course of hematological malignancies
por: Szymczyk, Agnieszka, et al.
Publicado: (2018)

The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review
por: Stefaniuk, Paulina, et al.
Publicado: (2020)

Prognostic significance of isochromosome 17q in hematologic malignancies
por: Koczkodaj, Dorota, et al.
Publicado: (2021)

Metformin - its anti-cancer effects in hematologic malignancies
por: Podhorecka, Monika
Publicado: (2021)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

Addendum: Prognostic significance of isochromosome 17q in hematologic malignancies
por: Koczkodaj, Dorota, et al.
Publicado: (2023)

Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2018)

In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia—A Narrative Review of Current Knowledge
por: Stefaniuk, Paulina, et al.
Publicado: (2022)

Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review
por: Stefaniuk, Paulina, et al.
Publicado: (2021)

COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic
por: Hus, Iwona, et al.
Publicado: (2023)

Bispecific Antibodies in the Treatment of Hematologic Malignancies
por: Duell, Johannes, et al.
Publicado: (2019)

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies
por: Kyriakidis, Ioannis, et al.
Publicado: (2021)

Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies
por: Mustafa, Nurulhuda, et al.
Publicado: (2022)

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies
por: Fratta, Elisabetta, et al.
Publicado: (2016)

Tumor-Associated Macrophages in Hematologic Malignancies: New Insights and Targeted Therapies
por: Petty, Amy J., et al.
Publicado: (2019)

Emerging Metabolic Targets in the Therapy of Hematological Malignancies
por: Leni, Zaira, et al.
Publicado: (2013)

The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies
por: Leśniak, Maria, et al.
Publicado: (2023)

Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
por: Marhelava, Katsiaryna, et al.
Publicado: (2019)

Antiphospholipid Antibodies and Lipids in Hematological Malignancies
por: Barreno-Rocha, Sonia Guadalupe, et al.
Publicado: (2022)

Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
por: Little, Jessica S., et al.
Publicado: (2021)

Trends in Malignant Glioma Monoclonal Antibody Therapy
por: Chekhonin, Ivan, et al.
Publicado: (2015)

Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease
por: Szymczyk, Agnieszka, et al.
Publicado: (2018)

Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients
por: Szymczyk, Agnieszka, et al.
Publicado: (2019)

Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies
por: Andreescu, Mihaela
Publicado: (2023)

Molecular-Targeted Therapies for Hematologic Malignancies
por: Bunting, Kevin D., et al.
Publicado: (2012)

A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies
por: Owen, Carolyn, et al.
Publicado: (2022)

Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Gallazzi, Marco, et al.
Publicado: (2022)

Renal Diseases Associated with Hematologic Malignancies and Thymoma in the Absence of Renal Monoclonal Immunoglobulin Deposits
por: Morel, Antoine, et al.
Publicado: (2021)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

Evaluation of SARS-CoV-2 Serological Testing in Patients with Multiple Myeloma and Other Hematologic Malignancies on Monoclonal Antibody Therapies
por: Mahimainathan, Lenin, et al.
Publicado: (2020)

Bispecific Antibodies in Hematological Malignancies: A Scoping Review
por: Omer, Mohamed H., et al.
Publicado: (2023)

Risk of infection associated with targeted therapies for solid organ and hematological malignancies
por: Ruiz-Camps, Isabel, et al.
Publicado: (2021)

Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19
por: Biernat, Monika Maria, et al.
Publicado: (2021)

Dendritic Cell Therapies for Hematologic Malignancies
por: Weinstock, Matthew, et al.
Publicado: (2017)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2014)

Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia
por: Podhorecka, Monika, et al.
Publicado: (2016)

Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies
por: Han, Yizhao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ejt0l42t8d1pc1ombeg1jvbvdp